Zions Bancorporation’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $3.15M | Buy |
36,639
+18,104
| +98% | +$1.96M | 0.2% | 102 |
|
|
2024
Q3 | $2.21M | Buy |
18,535
+6,726
| +57% | +$897K | 0.16% | 123 |
|
|
2024
Q2 | $1.69M | Sell |
11,809
-1,934
| -14% | -$256K | 0.14% | 125 |
|
|
2024
Q1 | $1.76M | Sell |
13,743
-531
| -4% | -$63.2K | 0.13% | 135 |
|
|
2023
Q4 | $1.48M | Buy |
14,274
+1,904
| +15% | +$188K | 0.1% | 156 |
|
|
2023
Q3 | $1.12M | Buy |
12,370
+4,302
| +53% | +$379K | 0.1% | 164 |
|
|
2023
Q2 | $653K | Buy |
8,068
+5,314
| +193% | +$434K | 0.06% | 230 |
|
|
2023
Q1 | $219K | Sell |
2,754
-1,048
| -28% | -$74.3K | 0.02% | 301 |
|
|
2022
Q4 | $257K | Buy |
3,802
+580
| +18% | +$34K | 0.02% | 297 |
|
|
2022
Q3 | $161K | Sell |
3,222
-290
| -8% | -$15.5K | 0.02% | 314 |
|
|
2022
Q2 | $196K | Sell |
3,512
-2
| -0.1% | -$111 | 0.02% | 314 |
|
|
2022
Q1 | $195K | Buy |
3,514
+144
| +4% | +$7.39K | 0.02% | 326 |
|
|
2021
Q4 | $189K | Hold |
3,370
| – | – | 0.02% | 309 |
|
|
2021
Q3 | $161K | Sell |
3,370
-1,756
| -34% | -$84.9K | 0.02% | 318 |
|
|
2021
Q2 | $215K | Buy |
5,126
+1,784
| +53% | +$69.2K | 0.02% | 286 |
|
|
2021
Q1 | $112K | Buy |
3,342
+438
| +15% | +$15.6K | 0.01% | 326 |
|
|
2020
Q4 | $101K | Buy |
2,904
+78
| +3% | +$2.7K | 0.01% | 316 |
|
|
2020
Q3 | $98K | Sell |
2,826
-28
| -1% | -$933 | 0.01% | 290 |
|
|
2020
Q2 | $93K | Sell |
2,854
-40
| -1% | -$1.28K | 0.01% | 278 |
|
|
2020
Q1 | $87K | Sell |
2,894
-1,498
| -34% | -$44.6K | 0.02% | 274 |
|
|
2019
Q4 | $127K | Sell |
4,392
-50
| -1% | -$1.38K | 0.02% | 293 |
|
|
2019
Q3 | $115K | Sell |
4,442
-84
| -2% | -$2.12K | 0.02% | 321 |
|
|
2019
Q2 | $116K | Sell |
4,526
-990
| -18% | -$24.5K | 0.02% | 290 |
|
|
2019
Q1 | $144K | Buy |
+5,516
| New | +$136K | 0.02% | 264 |
|
|
2018
Q2 | – | Sell |
-5,582
| Closed | -$137K | – | 623 |
|
|
2018
Q1 | $137K | Buy |
+5,582
| New | +$147K | 0.03% | 165 |
|
|
2017
Q4 | – | Sell |
-5,704
| Closed | -$137K | – | 862 |
|
|
2017
Q3 | $137K | Buy |
5,704
+4,970
| +677% | +$112K | 0.02% | 337 |
|
|
2017
Q2 | $15K | Sell |
734
-326
| -31% | -$6.58K | ﹤0.01% | 306 |
|
|
2017
Q1 | $18K | Sell |
1,060
-1,742
| -62% | -$30.3K | ﹤0.01% | 295 |
|
|
2016
Q4 | $51K | Sell |
2,802
-404
| -13% | -$7.32K | 0.01% | 233 |
|
|
2016
Q3 | $65K | Buy |
3,206
+530
| +20% | +$13.1K | 0.01% | 206 |
|
|
2016
Q2 | $74K | Sell |
2,676
-740
| -22% | -$20.3K | 0.01% | 183 |
|
|
2016
Q1 | $95K | Buy |
3,416
+2
| +0.1% | +$54 | 0.02% | 168 |
|
|
2015
Q4 | $85K | Sell |
3,414
-166
| -5% | -$4.59K | 0.01% | 163 |
|
|
2015
Q3 | $98K | Buy |
3,580
+3,380
| +1,690% | +$95.7K | 0.02% | 142 |
|
|
2015
Q2 | $5K | Sell |
200
-3,660
| -95% | -$103K | ﹤0.01% | 240 |
|
|
2015
Q1 | $103K | Buy |
+3,860
| New | +$88.9K | 0.02% | 164 |
|
Other funds holding NVO
F
Zions Bancorporation's NVO Position: Q4 2024 in Review
Zions Bancorporation increased its Novo Nordisk (NVO) stake by 98% in Q4 2024, buying an estimated $1.96M and bringing the position to 36,639 shares worth $3.15M. The position accounts for 0.2% of the portfolio, ranked #102.
Zions Bancorporation first reported a position in NVO in Q1 2015 and has held it in 36 quarters since. 1,664 funds tracked by Wall St. Rank hold NVO as of Q4 2024.
- Zions Bancorporation held 36,639 shares of Novo Nordisk worth $3.15M as of Q4 2024.
- Zions Bancorporation bought 18,104 Novo Nordisk shares in Q4 2024, an estimated $1.96M.
- Novo Nordisk made up 0.2% of Zions Bancorporation's portfolio in Q4 2024, its #102 holding.
- Zions Bancorporation first reported a position in Novo Nordisk in Q1 2015 and has held it in 36 quarters since.
- 1,664 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.
Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.